Clinical Trial Update: Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety and tolerability of trastuzumab deruxtecan and neratinib for HER2-altered metastatic or unresectable solid tumors; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Solid Neoplasm
• Unresectable Malignant Solid Neoplasm

Drugs mentioned

• Enhertu (trastuzumab deruxtecan) (trastuzumab deruxtecan)
• Nerlynx (neratinib) (neratinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm | Phase 1 | Status: SUSPENDED